This page is optimized for a taller screen. Please rotate your device or increase the size of your browser window.

Drug cost considerations for erythropoietic stimulating therapies (ESTs) agents in patients initiated at FDA-approved dosing: Results from practice patterns in a prospective observational study

CL Pashos, Q Wang, K Larholt, B Bookhart, RS McKenzie, CT Piech
ISPOR 2007


May 1, 2007